Aqemia’s ambition is to discover better and more innovative therapeutic molecules faster. Better molecules because our physics-based technology has unparalleled precision. More innovative molecules because we don’t rely on past data, we’re not stuck to staying close to what already exists. Faster because our precision implies fewer experiments.
Aqemia leverages a unique technology based on 8 years of research in quantum and statistical mechanics at Oxford (UK), Cambridge (UK), and École normale supérieure (Paris). Our algorithms are able to compute the affinity between molecules as precisely as experiments and 10 000x faster than the competition. This technology guides our AI towards the molecule that has a maximum affinity for the therapeutic target yet validates other biological and physico-chemical properties.
Aqemia is a spin-off from Ecole normale supérieure and PSL University created in 2019 by Maximilien Levesque (CEO) and Emmanuelle Martiano (COO).
No products posted yet
This data is part of our proprietary analytics report:
This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality